Story

Sagimet Biosciences Stock Climbs on Positive Acne Drug Data and Q2 Results

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Sagimet Biosciences Stock Climbs on Positive Acne Drug Data and Q2 Results
Text size
Background

Sagimet Biosciences (SGMT) shares climbed in pre-market trading after the company reported second-quarter financial results that beat Wall Street expectations and provided a positive clinical update for its lead drug candidate, denifanstat. The combination of in-line financials and promising trial data for its acne treatment fueled investor optimism in the biopharmaceutical firm's pipeline.

Clinical and Financial Updates

Sagimet reported a net loss of $14.0 million for the quarter ended June 30, a figure that came in slightly ahead of analyst consensus, according to Investing.com. The company also reaffirmed its strategic focus on its clinical pipeline, led by denifanstat.

Alongside the earnings release, the company presented new clinical data at a growth investor conference. The update included results from a Phase 3 trial conducted by its Chinese partner, Ascletis, which showed denifanstat demonstrated a significant improvement in treating acne.

Key findings from the China trial include:

  • A roughly 20-percentage-point improvement in treatment success versus placebo.
  • No serious adverse events were recorded among patients receiving the drug.
Sample IUX Markets – In-articleAd

Path Forward in the U.S.

Building on the positive data, Sagimet confirmed its plans to advance denifanstat in the United States. The company intends to launch a U.S. registrational Phase 3 trial for acne in the second half of 2026.

The planned trial aims to enroll 800 patients, including a significant cohort of 450 adolescents. As a commercial benchmark, management cited a potential monthly price point in the $1,200 to $1,500 range for the treatment.

Market Reaction

In response to the news, Sagimet's stock rose 3.4% to $9.84 in pre-open trading, touching a session high of $10.01 and approaching its 52-week peak of $10.06. The positive sentiment was supported by a consensus "Strong Buy" rating from ten covering analysts, who have an average 12-month price target of $28.50 on the stock, as reported by Investing.com.

Read next

More on Stocks
Back to latest news

LATEST